PLAU and prostate carcinoma: Accordingly, we used the PC3N-A6-WT and PC3N-A6-RR prostate cancer cells that express equivalent levels of the wild-type A6 subunit (cleavable to A6p via uPA treatment) and the non-cleavable subunit, respectively (Fig. 1a).